Shanghai ZJ Bio-Tech Co. Ltd. A (688317) - Total Liabilities

Latest as of March 2026: CN¥404.13 Million CNY ≈ $59.14 Million USD

Based on the latest financial reports, Shanghai ZJ Bio-Tech Co. Ltd. A (688317) has total liabilities worth CN¥404.13 Million CNY (≈ $59.14 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Shanghai ZJ Bio-Tech Co. Ltd. A - Total Liabilities Trend (2013–2025)

This chart illustrates how Shanghai ZJ Bio-Tech Co. Ltd. A's total liabilities have evolved over time, based on quarterly financial data. See 688317 working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Shanghai ZJ Bio-Tech Co. Ltd. A Competitors by Total Liabilities

The table below lists competitors of Shanghai ZJ Bio-Tech Co. Ltd. A ranked by their total liabilities.

Company Country Total Liabilities
Hunan Mendale Hometextile Co Ltd
SHE:002397
China CN¥1.11 Billion
Fenerbahce Futbol AS
IS:FENER
Turkey TL19.22 Billion
Traffic Control Technology Co Ltd
SHG:688015
China CN¥3.67 Billion
Mekonomen AB
ST:MEKO
Sweden Skr11.51 Billion
Claritev Corporation
NYSE:CTEV
USA $5.07 Billion
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365
China CN¥247.20 Million
Ipd Group Ltd
AU:IPG
Australia AU$172.83 Million
DINGDONG CAYMAN 2ADR/3 A
F:945
Germany €5.84 Billion

Liability Composition Analysis (2013–2025)

This chart breaks down Shanghai ZJ Bio-Tech Co. Ltd. A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Shanghai ZJ Bio-Tech Co. Ltd. A (688317) market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 25.19 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.12 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.11 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Shanghai ZJ Bio-Tech Co. Ltd. A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Shanghai ZJ Bio-Tech Co. Ltd. A (2013–2025)

The table below shows the annual total liabilities of Shanghai ZJ Bio-Tech Co. Ltd. A from 2013 to 2025.

Year Total Liabilities Change
2025-12-31 CN¥414.95 Million
≈ $60.72 Million
+171.10%
2024-12-31 CN¥153.06 Million
≈ $22.40 Million
-38.59%
2023-12-31 CN¥249.25 Million
≈ $36.47 Million
-54.13%
2022-12-31 CN¥543.44 Million
≈ $79.52 Million
+27.19%
2021-12-31 CN¥427.27 Million
≈ $62.52 Million
+2.47%
2020-12-31 CN¥416.97 Million
≈ $61.02 Million
+494.94%
2019-12-31 CN¥70.09 Million
≈ $10.26 Million
+49.20%
2018-12-31 CN¥46.98 Million
≈ $6.87 Million
+8.18%
2017-12-31 CN¥43.42 Million
≈ $6.35 Million
+1.78%
2016-12-31 CN¥42.66 Million
≈ $6.24 Million
-16.06%
2015-12-31 CN¥50.82 Million
≈ $7.44 Million
-43.07%
2014-12-31 CN¥89.28 Million
≈ $13.06 Million
+72.51%
2013-12-31 CN¥51.75 Million
≈ $7.57 Million
--

About Shanghai ZJ Bio-Tech Co. Ltd. A

SHG:688317 China Medical Devices
Market Cap
$460.30 Million
CN¥3.15 Billion CNY
Market Cap Rank
#12849 Global
#3820 in China
Share Price
CN¥16.37
Change (1 day)
+0.18%
52-Week Range
CN¥16.34 - CN¥28.98
All Time High
CN¥80.15
About

Shanghai ZJ Bio-Tech Co., Ltd. engages in the research and development, production, and sale of molecular diagnostic reagents and instruments in China and internationally. It offers nucleic acid and real-time PCR kits, as well as consumables. The company was founded in 2005 and is based in Shanghai, China.